Browse the corpus

Calcineurin inhibitors (CNIs) are a class of immunosuppressants utilized to effectively manage various autoimmune disorders, including, but not limited to, lupus nephritis, idiopathic inflammatory myositis, interstitial lung disease, and atopic dermatitis. In addition, they serve as essential components for immunosuppression in solid organ transplantation. CNIs generally bind with high affinity to specific cytoplasmic receptors known as immunophilins, which include cyclophilin and FK-binding proteins. Through targeted inhibition of calcineurin, these medications disrupt the transcription of interleukin-2 and other cytokines within T lymphocytes, thus disrupting the activation, proliferation, and differentiation of T cells. Although their primary effect is on T-helper cells, these inhibitors also concurrently inhibit T suppressor and T cytotoxic cells. This activity illustrates the indications, mechanism of action, and contraindications of CNIs, emphasizing their value in various conditions. This activity also highlights the essential elements such as off-label uses, dosing, pharmacokinetics, monitoring, and relevant interactions of CNIs that are relevant to healthcare professionals across various specialties in their daily clinical practice. Objectives: Identify the appropriate indications for calcineurin inhibitor therapy in autoimmune conditions and solid organ transplantation. Screen patients for contraindications and risk factors before initiating calcineurin inhibitor therapy, considering their medical history, organ transplant status, renal function, hypertension, and concurrent medications. Assess patients regularly for calcineurin inhibitor efficacy and safety, drug levels, renal function, blood pressure, immunosuppressive effects, and potential adverse effects to optimize therapy and ensure patient safety. Select the most appropriate calcineurin inhibitor agent based on patient-specific factors, disease state, and drug interactions while considering individual preferences and comorbidities. Access free multiple choice questions on this topic.

Signs, Symptoms, and Management of Overdose In cases of drug overdose in individuals taking CNIs, forced vomiting and gastric lavage could be beneficial within the first 2 hours after the drug administration. However, these measures should not be attempted in unconscious patients to avoid the risk of aspiration pneumonia. In addition, the drug may cause transient hepatotoxicity and nephrotoxicity, but these adverse effects usually resolve once the drug is withdrawn. Reports indicate that oral doses of cyclosporine up to 10 g, which is approximately 150 mg/kg, are tolerable and only cause mild symptoms such as drowsiness, headache, and tachycardia. However, moderate-to-severe reversible renal impairment has also been reported in patients. Accidental drug overdose can occur in premature neonates when the drug is administered intramuscularly. Management for cyclosporine overdose primarily involves providing supportive and symptomatic care. Tacrolimus overdose occurs when the drug exceeds the regular dose by approximately 30 times, and fortunately, nearly all patients recover completely from such incidents. Adverse reactions to tacrolimus overdose encompass a range of symptoms, such as tremors, abnormal renal function, high blood pressure, and peripheral edema. Furthermore, lethargy and transient urticaria cases have been reported in the acute setting. Management primarily revolves around providing supportive and symptomatic treatment to patients, as dialysis does not effectively remove the drug. Activated charcoal is recommended in cases of acute overdose, although there is limited evidence, and its efficacy remains uncertain. The use of charcoal hemoperfusion for drug removal is not extensively reported or established.[54] No reported cases of pimecrolimus overdose have been documented, and accidental oral intake is also uncommon. However, in the event of oral ingestion, immediate medical intervention should be sought by patients. As voclosporin is a relatively novel drug, limited literature regarding its toxicity profile is currently available.

CNIs effectively treat a diverse range of immune-mediated conditions; however, excessive dosing can lead to complications. Consequently, a thorough understanding of the drugs within this class, including their mechanisms of action, indications, potential toxicities, and monitoring guidelines, is essential for clinicians to advise and educate their patients effectively. Furthermore, a collaborative interprofessional approach is vital for managing chronic conditions necessitating CNI therapy in patients. This fosters open communication among healthcare providers engaged in patient care and education. CNIs are prescribed by various specialists, including transplant surgeons, dermatologists, rheumatologists, hepatologists, and nephrologists, each addressing specific indications based on their expertise. Prescribing these drugs necessitates an interprofessional approach involving active participation from all healthcare providers to ensure comprehensive patient care. Compliance is enhanced through a robust clinician-patient relationship, which contributes to improved long-term patient-reported efficacy and safety outcomes. Primary care providers are critical in reinforcing medication compliance. Clinical pharmacists are responsible for conducting meticulous medication reconciliation and verifying appropriate dosing, considering the narrow therapeutic index of the CNIs. The nursing staff is critical in ensuring medication safety by confirming dosages before administration, assessing patient records for potential adverse reactions, offering patient counseling, and communicating any arising concerns to the prescribing clinician.

CNIs are prescribed by various specialists, including transplant surgeons, dermatologists, rheumatologists, hepatologists, and nephrologists, each addressing specific indications based on their expertise. Prescribing these drugs necessitates an interprofessional approach involving active participation from all healthcare providers to ensure comprehensive patient care. Compliance is enhanced through a robust clinician-patient relationship, which contributes to improved long-term patient-reported efficacy and safety outcomes. Primary care providers are critical in reinforcing medication compliance. Clinical pharmacists are responsible for conducting meticulous medication reconciliation and verifying appropriate dosing, considering the narrow therapeutic index of the CNIs. The nursing staff is critical in ensuring medication safety by confirming dosages before administration, assessing patient records for potential adverse reactions, offering patient counseling, and communicating any arising concerns to the prescribing clinician. In cases of nephrotoxicity, patients are advised to promptly consult with a nephrologist for appropriate management of the condition. Furthermore, consultation with an infectious disease specialist is necessary to ensure proper treatment and care for patients and address infections caused by BK viremia after organ transplantation. In accidental overdose, emergency room physicians are critical in rapidly stabilizing the patients, after which they may be transferred to the Medical Intensive Care Unit (MICU). Managing critically ill patients who have experienced CNI overdose requires the expertise of critical care physicians and toxicologists to ensure comprehensive and effective treatment of patients. Utilizing an interprofessional team approach that fosters open communication among physicians, advanced practice practitioners, specialists, pharmacists, and nurses can significantly enhance patient outcomes and minimize the adverse effects associated with CNIs.